The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review

This publication has 54 references indexed in Scilit:

• Predicting Outcomes in Prostate Cancer: How Many More Nomograms Do We Need?
  Journal of Clinical Oncology, 2007
• The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically‐based screening strategy
  International Journal of Cancer, 2007
• The Association Between Total Prostate Specific Antigen Concentration and Prostate Specific Antigen Velocity
  Journal of Urology, 2007
• Using prostate‐specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer
  BJU International, 2006
• Making Sense of Prostate Specific Antigen: Improving its Predictive Value in Patients Undergoing Prostate Biopsy
  Journal of Urology, 2006
• A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55–75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam)
  The Prostate, 2005
• Assessing Benefit and Risk in the Prevention of Prostate Cancer: The Prostate Cancer Prevention Trial Revisited
  Journal of Clinical Oncology, 2005
• Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal
  JNCI Journal of the National Cancer Institute, 2005
• Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-Analysis
  European Urology, 2005
• EFFECTS OF SYSTEMATIC 12-CORE BIOPSY ON THE PERFORMANCE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER DETECTION
  Journal of Urology, 2004